ARRIVENT BIOPHARMA, INC. Investing Cash Flow
ARRIVENT BIOPHARMA, INC. (AVBP) reported Investing Cash Flow of $49.65 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-12
- ARRIVENT BIOPHARMA, INC. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $46.07M, a 231.21% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $3.58M, a 90.27% decline year-over-year.
- ARRIVENT BIOPHARMA, INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$71.20M.
- ARRIVENT BIOPHARMA, INC. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$50.76M.
- ARRIVENT BIOPHARMA, INC. net cash provided by (used in) investing activities for fiscal 2025 was -$71.23M.
- ARRIVENT BIOPHARMA, INC. net cash provided by (used in) investing activities for fiscal 2024 was -$192.47M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $46.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $49.65M 10-Q · filed 2026-08-12 | -$21.55M derived: sum of 3 quarters · filed 2026-08-12 | -$72.31M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $3.58M 10-Q · filed 2026-05-11 | -$67.62M derived: sum of 2 quarters · filed 2026-05-11 | -$118.38M derived: sum of 3 quarters · filed 2026-05-11 | -$104.47M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$71.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$121.96M derived: sum of 2 quarters · filed 2026-03-05 | -$108.05M derived: sum of 3 quarters · filed 2026-08-12 | -$71.23M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$50.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$36.85M derived: sum of 2 quarters · filed 2026-08-12 | -$29.00K 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $13.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $50.73M 10-Q · filed 2026-08-12 | ||
| 2025-03-31 | $36.82M 10-Q · filed 2026-05-11 | |||
| 2024-12-31 | -$192.47M 10-K · filed 2026-03-05 | |||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$25.00M 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | -$25.00M 10-Q · filed 2024-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |